Edit
Mestag Therapeutics
https://mestagtx.com/Last activity: 19.05.2026
Active - Reference to Mestag Therapeutics
Mestag Therapeutics is exploiting emerging insights in the role of fibroblast subpopulations to develop pioneering transformative therapies in inflammatory disease and oncology.
Employees: 11-50
Total raised: $56M
Founded date: 2020
Investors 2
| Date | Name | Website |
| - | SV Health ... | svhealthin... |
| 07.08.2021 | GV | gv.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 03.08.2021 | Seed | $45M | - |
| 20.04.2021 | Seed | $11M | - |
Mentions in press and media 14
| Date | Title | Description |
| 19.05.2026 | Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial | — STARLYS trial to evaluate the potential of MST-0312, a targeted lymphotoxin-beta (LTBR) agonist bispecific antibody, as a novel therapeutic strategy for the treatment of solid tumors. — Study to evaluate tertiary lymphoid structure (TLS) ... |
| 17.03.2026 | Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic | -- Financing brings total funds committed to date to >$95 million -- Proceeds support the STARLYS clinical trial evaluating targeted LTBR agonist MST-0312 in solid tumors, together with platform and pipeline activities in inflammatory di... |
| 16.09.2025 | Dualitas Launches With $65 Million Series A to Advance Novel Bispecific Antibody Pipeline in Immune and Inflammatory Disease | - Versant Ventures and Qiming Venture Partners USA co-led financing with participation from founding investor SV Health Investors and new strategic investors Chugai Venture Fund, Eli Lilly and Company, and Alexandria Venture Investments - L... |
| 04.03.2025 | Mestag Therapeutics Appoints Dr. Matthew Sleeman as Chief Scientific Officer | Mestag Therapeutics (“Mestag”), a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease and cancer, today announced that Matthew Sleeman, PhD, has been appointed Chief Scientific Officer. “Ma... |
| 09.12.2024 | Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform | Cambridge, UK, December 9, 2024 – Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, today announced that Johnson & Johnson* has exclusively licensed a novel, undisclosed targe... |
| 08.10.2024 | Mestag Therapeutics Announces License and Research Collaboration with MSD to Identify Novel Targets for Inflammatory Diseases | – Exclusively deploys Mestag’s proprietary RAFT platform to interrogate the pathogenic role of fibroblasts in inflammatory disease for novel target discovery Cambridge, UK, October 8, 2024 – Mestag Therapeutics (“Mestag”), a biotech company... |
| 28.08.2024 | Mestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300 | – Innovate UK, part of UK Research and Innovation, is investing £12 million in innovation projects to advance next-generation immunotherapies for cancer, of which £1.5 million has been awarded to Mestag – Bispecific antibody MST-0300 is a f... |
| 27.09.2021 | FIERCE BIOTECH NAMES MESTAG THERAPEUTICS AS ONE OF ITS “FIERCE 15” BIOTECH COMPANIES OF 2021 | Cambridge, UK, 27 September 2021 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today announced that Fierce Biotech has named it as one of 2021’s Fierce 15 biotechnology companies, designa... |
| 04.08.2021 | Mestag Therapeutics extends seed financing to $45 million and welcomes new investors | Mestag Therapeutics extends seed financing to $45 million and welcomes new investors 04-08-2021 Mestag Therapeutics, a breakthrough inflammatory disease and immuno-oncology company, has announced the closing of its oversubscribed Seed exten... |
| 03.08.2021 | Mestag Therapeutics Extends Seed Financing to $45 Million and Welcomes New Investors Forbion, GV (formerly Google Ventures) and Northpond Ventures | - Oversubscribed seed round supports the development of impactful medicines targeting activated fibroblast populations in inflammatory disease and cancer |
Show more